Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Non-Current Debt (2019 - 2025)

Historic Non-Current Debt for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $47.1 million.

  • Biodesix's Non-Current Debt rose 3045.8% to $47.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.1 million, marking a year-over-year increase of 3045.8%. This contributed to the annual value of $36.4 million for FY2024, which is 335.84% up from last year.
  • As of Q3 2025, Biodesix's Non-Current Debt stood at $47.1 million, which was up 3045.8% from $46.8 million recorded in Q2 2025.
  • Biodesix's 5-year Non-Current Debt high stood at $47.1 million for Q3 2025, and its period low was $4.9 million during Q3 2022.
  • Moreover, its 5-year median value for Non-Current Debt was $30.0 million (2021), whereas its average is $28.1 million.
  • As far as peak fluctuations go, Biodesix's Non-Current Debt crashed by 8371.98% in 2022, and later surged by 41127.05% in 2023.
  • Over the past 5 years, Biodesix's Non-Current Debt (Quarter) stood at $10.0 million in 2021, then surged by 150.22% to $25.0 million in 2022, then soared by 40.88% to $35.2 million in 2023, then increased by 3.36% to $36.4 million in 2024, then rose by 29.4% to $47.1 million in 2025.
  • Its last three reported values are $47.1 million in Q3 2025, $46.8 million for Q2 2025, and $36.7 million during Q1 2025.